Cimzia ^*

Cimzia (generic name: certolizumab pegol) is a biologic medication designed to treat certain autoimmune and inflammatory conditions by targeting tumor necrosis factor-alpha (TNF-alpha). As an anti-TNF medication, Cimzia reduces inflammation, offering relief in conditions such as:

• rheumatoid arthritis (RA)
• psoriatic arthritis (PsA)
• ankylosing spondylitis (AS)
• non-radiographic axial spondyloarthritis (nr-axSpA)
• moderate to severe Crohn’s disease
• Plaque psoriasis.

These conditions often involve chronic inflammation where the immune system attacks the body’s tissues, leading to pain, stiffness, and in Crohn’s disease, digestive issues. Cimzia is used to treat moderate to severe plaque psoriasis. Plaque psoriasis is an inflammatory disease of the skin that can also affect the scalp and nails. Cimzia works by neutralizing TNF-alpha, a protein that plays a key role in the inflammatory process. Excessive TNF-alpha can lead to prolonged inflammation and tissue damage, so by binding to and inhibiting this protein, Cimzia helps manage inflammation and may slow disease progression. As a pegylated, humanized antibody fragment, Cimzia has a unique molecular structure that extends its action, allowing less frequent dosing compared to some other biologics. This pegylation feature makes it a long-acting option for patients needing ongoing management of autoimmune symptoms. For further information, the Mayo Clinic provides an overview of biologic therapies in treating autoimmune diseases like Crohn’s.

Dosage

The usual dosage of Cimzia varies based on the condition it treats. It is administered as a subcutaneous injection. In rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, the usual initial dose of 400 mg is given at weeks 0, 2, and 4, followed by a maintenance dose of 200 mg every two weeks. In Crohn’s disease, a similar initial dosing schedule is followed, but the maintenance dose may vary. If a dose is missed, it should be administered as soon as possible, and patients should return to their regular schedule without doubling the dose.

Storage

Cimzia should be stored in the refrigerator at 2-8°C (36-46°F) and must not be frozen. The pre-filled syringes or vials should remain in their original packaging to protect from light. If necessary, Cimzia can be kept at room temperature (up to 25°C or 77°F) for up to 7 days, but should be discarded if unused beyond that period. If in any doubt, consult our blog on safe medicine management.

Common Questions About Cimzia

How is Cimzia administered?

Cimzia is given as a subcutaneous injection, which means it is injected under the skin, usually in the thigh or abdomen. The typical dosing regimen starts with 400 mg doses administered at intervals in the first month. Afterward, a maintenance dose is provided, generally 200 mg every two weeks. In Crohn’s disease, the dosing may differ slightly. Patients can be trained to self-administer injections at home if recommended by their healthcare provider.

How does certolizumab pegol work?

Certolizumab pegol, the active ingredient in Cimzia, works by inhibiting TNF-alpha, a protein that plays a major role in inflammation. By blocking TNF-alpha, certolizumab pegol reduces inflammation and helps manage symptoms in autoimmune conditions. This mechanism helps alleviate symptoms like pain, swelling, and joint stiffness in patients with arthritis or inflammatory bowel disease, leading to improved quality of life.

How effective is Cimzia for rheumatoid arthritis?

Clinical trials have shown Cimzia to be effective in reducing symptoms of rheumatoid arthritis, including joint pain, swelling, and stiffness. Many patients report improvements in their physical function and quality of life after beginning Cimzia therapy. It’s generally used for long-term management and may be combined with other treatments under a healthcare provider’s supervision.

What are anti-TNF drugs, and how do they work?

Anti-TNF drugs, like Cimzia, block the activity of tumor necrosis factor-alpha (TNF-alpha), a protein that promotes inflammation in the body. By inhibiting TNF-alpha, these drugs reduce inflammation, helping to manage symptoms in autoimmune diseases. Anti-TNFs are commonly used to treat conditions like rheumatoid arthritis, psoriatic arthritis, and Crohn’s disease.